Biosplice Announces Collaboration with Novo Nordisk in Diabetes Biosplice enters into a pre-clinical collaboration with Novo Nordisk to develop inhibitors of DYRK for diabetes

First Subject Dosed in Biosplice Therapeutics Phase 1b Clinical Trial in Oncology SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major...